1-{[4-(2-methyl-quinolin-4-ylmethoxy)-benzoylamino]-methyl}-cyclopropanecarboxylic acid | 362703-22-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-{[4-(2-methyl-quinolin-4-ylmethoxy)-benzoylamino]-methyl}-cyclopropanecarboxylic acid
• 英文别名: 1-[[[4-[(2-Methylquinolin-4-yl)methoxy]benzoyl]amino]methyl]cyclopropane-1-carboxylic acid
• CAS: 362703-22-8
• 化学式: C₂₃H₂₂N₂O₄
• 分子量: 390.439
• InChiKey: XEBRNVWQUYPCHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  88.5
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme
  申请人：——

  公开号：US20040116491A1

  公开（公告）日：2004-06-17

  The present application describes novel hydantoin derivatives of formula (I): 1 or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, L, and R 11 are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase, or a combination thereof.

  本申请描述了式 (I) 的新型海因衍生物： 1 或其药学上可接受的盐或原药形式，其中 A、L 和 R 11 可用作基质金属蛋白酶 (MMP)、TNF-&agr; 转换酶 (TACE)、凝集素酶或其组合的抑制剂。
• EP1558581A4
  申请人：——

  公开号：EP1558581A4

  公开（公告）日：2007-07-25
• TRIAZOLONE AND TRIAZOLETHIONE DERIVATIVES
  申请人：Bristol-Myers Squibb Company

  公开号：EP1558581A2

  公开（公告）日：2005-08-03
• US7074810B2
  申请人：——

  公开号：US7074810B2

  公开（公告）日：2006-07-11
• [EN] TRIAZOLONE AND TRIAZOLETHIONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME<br/>[FR] DERIVES DE LA TRIAZOLONE ET DE LA TRIAZOLETHIONE, INHIBITEURS DES METALLOPROTEINASES DE MATRICES ET/OU DE L'ENZYME DE CONVERSION DU TNF DOLLAR G(A)
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2004032846A2

  公开（公告）日：2004-04-22

  The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, L, and R11 are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-a converting enzyme (TACE), aggrecanase, or a combination thereof.